Hepatitis B virus deoxyribonucleic acid in serum during hepatitis B e antigen clearance in corticosteroid-treated severe chronic active hepatitis B
- PMID: 3678739
- DOI: 10.1016/0016-5085(87)90248-4
Hepatitis B virus deoxyribonucleic acid in serum during hepatitis B e antigen clearance in corticosteroid-treated severe chronic active hepatitis B
Abstract
The relationship between hepatitis B virus deoxyribonucleic acid in serum and histologic activity was determined in 11 patients with corticosteroid-treated severe chronic active hepatitis B who underwent clearance of hepatitis B e antigen. All patients cleared hepatitis B virus deoxyribonucleic acid from the serum, and clearance preceded the loss of hepatitis B e antigen by 9-49 mo (mean 24 +/- 4 mo). Seropositivity for hepatitis B virus deoxyribonucleic acid was always associated with histologic features of chronic active hepatitis. Resolution of histologic activity followed the loss of hepatitis B virus deoxyribonucleic acid from the serum and it preceded clearance of hepatitis B e antigen in all patients. A transient elevation of serum aspartate aminotransferase activity occurred in 5 patients at the time that absence of hepatitis B virus deoxyribonucleic acid in serum was first demonstrated, and it was followed by resolution of histologic activity. The serum level of hepatitis B virus deoxyribonucleic acid slowly decreased or remained unchanged in all but 1 patient during long-term corticosteroid therapy. We conclude that hepatitis B virus deoxyribonucleic acid in serum is associated with histologic activity in corticosteroid-treated patients with severe chronic active hepatitis B. Disappearance of hepatitis B virus deoxyribonucleic acid from the serum precedes the loss of histologic activity and clearance of hepatitis B e antigen. Serum hepatitis B virus deoxyribonucleic acid levels usually do not increase during long-term corticosteroid therapy.
Similar articles
-
Hepatitis B virus replication in steroid-treated severe HBsAg-positive chronic active hepatitis.Dig Dis Sci. 1985 Feb;30(2):97-103. doi: 10.1007/BF01308192. Dig Dis Sci. 1985. PMID: 3967568
-
Frequency and significance of immunoglobulin M antibody to hepatitis B core antigen in corticosteroid-treated severe chronic active hepatitis B.Mayo Clin Proc. 1988 Feb;63(2):119-25. doi: 10.1016/s0025-6196(12)64944-1. Mayo Clin Proc. 1988. PMID: 3339905
-
Persistence of serum hepatitis B virus deoxyribonucleic acid in hepatitis B surface antigen-positive patients with chronic persistent hepatitis treated with prednisone.Gastroenterology. 1987 Apr;92(4):862-6. doi: 10.1016/0016-5085(87)90958-9. Gastroenterology. 1987. PMID: 3556993
-
Chronic hepatitis: pathogenesis and treatment.Aust N Z J Med. 1986 Feb;16(1):101-7. doi: 10.1111/j.1445-5994.1986.tb01139.x. Aust N Z J Med. 1986. PMID: 3518687 Review. No abstract available.
-
Chronic hepatitis. To treat or not to treat?Med Clin North Am. 1978 Jan;62(1):71-85. doi: 10.1016/s0025-7125(16)31823-5. Med Clin North Am. 1978. PMID: 340820 Review. No abstract available.
Cited by
-
Treatment of polyarteritis nodosa related to hepatitis B virus with interferon-alpha and plasma exchanges.Ann Rheum Dis. 1994 May;53(5):334-7. doi: 10.1136/ard.53.5.334. Ann Rheum Dis. 1994. PMID: 7912504 Free PMC article.
-
Nucleotide sequence analysis of precore and proximal core regions in patients with chronic hepatitis B treated with interferon.Dig Dis Sci. 1995 Jan;40(1):1-7. doi: 10.1007/BF02063933. Dig Dis Sci. 1995. PMID: 7821093 Clinical Trial.
-
Treatment of hepatitis B virus-related polyarteritis nodosa: two case reports and a review of the literature.Clin Rheumatol. 2004 Apr;23(2):172-6. doi: 10.1007/s10067-003-0857-4. Epub 2004 Feb 11. Clin Rheumatol. 2004. PMID: 15045636
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical